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Oxidative stress is emerging as an important contributor to the pathogenesis of colorectal cancer (CRC), however,
the molecular mechanisms by which the disturbed redox balance regulates CRC development remain undefined.
Using a liquid chromatography–tandem mass spectrometry-based lipidomics, we found that epox
yketooctadecenoic acid (EKODE), which is a lipid peroxidation product, was among the most dramatically
increased lipid molecules in the colon of azoxymethane (AOM)/dextran sodium sulfate (DSS)-induced CRC mice.
This is, at least in part, due to increased oxidative stress in colon tumors, as assessed by analyzing gene
expression of oxidative markers in AOM/DSS-induced CRC mice and human CRC patients in the Cancer Genome
Atlas (TCGA) database. Systemic, short-time treatment with low-dose EKODE increased the severity of DSSinduced colitis, caused intestinal barrier dysfunction and enhanced lipopolysaccharide (LPS)/bacterial trans
location, and exacerbates the development of AOM/DSS-induced CRC in mice. Furthermore, treatment with
EKODE, at nM doses, induced inflammatory responses via JNK-dependent mechanisms in both colon cancer cells
and macrophage cells. Overall, these results demonstrate that the lipid peroxidation product EKODE is an
important mediator of colonic inflammation and colon tumorigenesis, providing a novel mechanistic linkage
between oxidative stress and CRC development.

1. Introduction

tumorigenesis [4–6]. In an effort to systematically analyze how lipid
metabolites are deregulated in CRC, we performed a liquid chroma
tography–tandem mass spectrometry (LC-MS/MS)-based lipidomics,
which can measure >100 lipid metabolites derived from enzymatic and
non-enzymatic processes, in a well-established azoxymethane (AOM)/
dextran sodium sulfate (DSS)-induced CRC model in mice [7]. Here, we
found that epoxyketooctadecenoic acid (EKODE), which was a lipid
peroxidation-derived compound, was among the most dramatically
increased lipid metabolites in the colon tissues of AOM/DSS-induced
CRC mice compared to those of the healthy mice (Fig. 1). This leads to
our hypothesis that formation of EKODE could provide a novel mecha
nistic linkage between oxidative stress and CRC development. To date,
the effects of EKODE on inflammation and cancer are unknown. To test
our hypothesis, here we determined the functional roles of EKODE in
regulating colonic inflammation and colon carcinogenesis in both ani
mal and cell culture models.

Colorectal cancer (CRC) is the third most common cancer and the
second leading cause of cancer-related death in the United States [1],
emphasizing the need for discovery of novel cellular targets which are
crucial in the pathogenesis of CRC. Oxidative stress, which is a common
feature of many human diseases including CRC, is emerging as an
important contributor to the development of CRC [2,3]. However, the
molecular mechanisms by which the disturbed redox balance promotes
CRC development remain undefined [2]. It is important to better un
derstand the underlying mechanisms, in order to identify novel patho
genic factors of CRC, facilitating development of diagnosis markers
and/or intervention targets to reduce the risks of CRC.
Emerging research supports that lipid metabolites, such as enzymatic
metabolites of fatty acids (e.g. eicosanoids) and non-enzymatic oxida
tion products of fatty acids (e.g. lipid peroxidation products), are
important signaling molecules that regulate inflammation and
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2. Materials and methods

week, the mice were sacrificed to collect blood and colon tissues for
analysis.

2.1. Animal experiments

2.5. Animal protocol 4: effects of EKODE on AOM/DSS-induced CRC

All animal experiments were conducted in accordance with the
protocols approved by the Institutional Animal Care and Use Committee
of the University of Massachusetts Amherst. C57BL/6 male mice
(Charles River) were maintained in a standard animal facility at the
University of Massachusetts Amherst.

C57BL/6 mice (age = 6 weeks) were maintained on a standard
mouse chow and treated with 10 mg/kg AOM via intraperitoneal in
jection. At week 1 post the AOM injection, they were treated with 2%
DSS in drinking water for 1 week. At week 3 post the AOM injection, the
mice were treated with EKODE (dose = 1 mg/kg/day) or vehicle DMSO
(volume = 20 μL) via intraperitoneal injection for 10 days. At week 9.5
post the AOM injection, the mice were sacrificed to collect blood and
colon tissues for analysis.

2.2. Animal protocol 1: DSS-induced colitis in mice
C57BL/6 mice (age = 6 weeks) were maintained on a modified AIN93G diet (see diet composition in Supplementary Table S1) throughout
the experiment. After 2 weeks of diet treatment, the mice were treated
with drinking water with or without 2% DSS (MP Biomedicals) for 1
week. At end of the experiment, the mice were sacrificed to collect tis
sues for analysis, as we described [8].

2.6. Flow cytometry analysis of immune cell infiltration in colon tissues
Distal colon tissues were dissected and digested with Hank’sbalanced salt solution (Lonza) supplemented with 1 mM dithiothreitol
(DTT) and 5 mM EDTA overnight at 4 ◦ C. After filtering through 70 μm
cell strainer (BD Biosciences), the single-cell suspensions were stained
with FITC-conjugated anti-mouse CD45 antibody, PerCP/Cy5.5conjugated anti-mouse F4/80 antibody, PE/Cy7-conjugated antimouse Ly-6G/Ly-6C (GR-1) antibody, isotype control antibody and
Zombie Violet™ dye (BioLegend). Data were acquired using BD
LSRFortessa™ cell analyzer (BD Biosciences) and analyzed using FlowJo
software (FlowJo LLC). In our analysis, leukocytes were identified as
CD45+ cells, macrophages were identifed as CD45+ F4/80+ cells, and
neutrophils were identified as CD45+ GR-1+ cells.

2.3. Animal protocol 2: AOM/DSS-induced CRC in mice
C57BL/6 mice (age = 6 weeks) were maintained on a modified AIN93G diet throughout the experiment. After 2 weeks of diet treatment, the
mice were divided into two groups: (1) the mice in the CRC group were
treated with 10 mg/kg AOM (Sigma-Aldrich) via intraperitoneal injec
tion; after 1 week, the mice were stimulated with 2% DSS in drinking
water for 1 week; and (2) the mice in the control group were not treated
with AOM or DSS. At week 9.5 post the AOM injection, the mice were
sacrificed for analysis, as we described [7,8].

2.7. H&E staining and immunohistochemistry

2.4. Animal protocol 3: effects of EKODE on DSS-induced colitis in mice

Dissected colon tissues were fixed in formalin (Thermo Fisher Sci
entific) for 48 h. Then the tissues were embedded in paraffin, sliced (5μm), dewaxed in serial xylene (Thermo Fisher Scientific) and rehydrated
through graded ethanol solutions (Pharmco-Aaper). For H&E staining,
the slides are stained with hematoxylin and eosin (SigmaAldrich), and

C57BL/6 mice (age = 6 weeks) were maintained on a standard
mouse chow, and treated with 2% DSS in drinking water to induce co
litis, as well as intraperitoneal injection with EKODE (dose = 1 mg/kg/
day, Cayman Chemical) or vehicle DMSO (volume = 20 μL). After 1

Fig. 1. Lipidomics analysis showed that EKODE was among the most dramatically increased lipids in the colon of AOM/DSS-induced CRC mice. A, LC-MS/MS
profiling of bioactive lipids in the colon, the Y-axis is expressed as relative change of lipid metabolite in the colon of AOM/DSS-induced CRC mice (n = 10 mice
per group) vs. control mice (n = 6 mice per group). B, Structures and biosynthetic scheme of 13-HoTrE, epoxygenated fatty acids (using EpOME as an example),
and EKODE.
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examined with a light microscopy (Nikon Instruments). The histological
scores were evaluated by blind observers according to the following
measures: crypt architecture, degree of inflammatory cell infiltration,
muscle thickening, goblet cell depletion and crypt abscess. The patho
logical score is the sum of each individual score. For immunohisto
chemistry, antigen retrieval was performed by heating the sections in
0.01 M citrate buffer (pH 6.0) to 95 ◦ C for 10 min. The slides were
incubated with primary antibodies against occludin, proliferating cell
nuclear antigen (PCNA) and β-catenin (Cell Signaling Technology)
overnight at 4 ◦ C. Horseradish peroxidase (HRP)-conjugated secondary
antibodies were then applied to the sections, followed by the chromogen
4-diaminobenzidine staining according to the instructions of HRP/DAB
(ABC) Detection IHC Kit (Abcam). Sections were then counterstained
with hematoxylin for 1 min and observed under a light microscope
(Nikon Instruments).

serum albumin (BSA, Thermo Fisher Scientific) buffer for 1 h at room
temperature, then incubated with primary antibodies against phosphoJNK, JNK, IκBα, p65, Lamin, IL6 (Cell Signaling Technology) and
β-actin (Sigma-Aldrich) in 5% BSA solution at 4 ◦ C overnight. The
membrane was then probed with LI-COR IRDye 800 C W goat anti-rabbit
and IRDye 680RD goat anti-mouse secondary antibodies and then
detected using the Odyssey imaging system (LI-COR). Quantification of
immunoblotting was performed using ImageJ Software (NIH). Data are
normalized against those of the corresponding β-actin.
2.12. LC-MS/MS analysis
To extract lipid metabolites from colon tissues, ~100 mg tissues were
mixed with an antioxidant solution (0.2 mg/mL butylated hydrox
ytoluene and 0.2 mg/mL triphenylphosphine in methanol), deuterated
internal standards, and 400 μL extract solution (0.1% acetic acid with
0.2 mg/mL butylated hydroxytoluene in a methanol solution), and then
homogenized; the resulting homogenates were kept in − 80 ◦ C over
night. After centrifugation of the homogenates, the pellets were washed
with methanol (containing 0.1% butylated hydroxytoluene and 0.1%
acetic acid) and then combined with the supernatant. The combined
solutions were loaded onto pre-washed Waters® Oasis solid phase
extraction (SPE) cartridges, washed with a solution of 95:5 water/
methanol with 0.1% acetic acid, the analytes were eluted with methanol
and ethyl acetate, dried using a centrifugal vacuum evaporator, then
reconstituted in methanol for LC-MS/MS analysis. The LC-MS/MS
analysis was carried out using an Agilent 1200SL HPLC system (Agi
lent, Santa Clara, CA) coupled to a 4000 QTRAP MS/MS (AB Sciex,
Foster City, CA) as described in our previous report [7].

2.8. qRT-PCR analysis of gene expression in tissues and cells
For tissues analysis, colon tissues from the same locations or spleen
tissues were grounded after freezing in liquid nitrogen and then added
TRIzol reagent (Ambion). For cell assay, the HCT-116 or RAW 264.7
cells were treated with 300 nM EKODE or DMSO vehicle in complete
medium for 24 h, then the cells were washed with cold PBS and added
with TRIzol reagent. Total RNA was isolated from tissues or cells based
on manufacturer’s instructions of TRIzol reagent. The concentration and
quality of RNA was measured by NanoDrop Spectrophotometer (Thermo
Fisher Scientific), then the RNA was reverse transcribed into cDNA using
the High Capacity cDNA Reverse Transcription kit (Applied Biosystems)
according to manufacturer’s instructions. qRT-PCR was performed using
a DNA Engine Opticon system (Bio-Rad Laboratories) with Maxima
SYBR-green Master Mix (Thermo Fisher Scientific). The sequences of
primers are listed in Supplementary Table S2. The results of target genes
were normalized to glyceraldehyde-3-phosphate dehydrogenase
(Gapdh) and expressed to control mice using the 2 -ΔΔCt method.

2.13. Data analysis
Data are expressed as mean ± SEM. For the comparison between two
groups, Shapiro-Wilk test was used to verify the normality of data; when
data were normally distributed, statistical significance was determined
using two-side t-test; otherwise, significance was determined by Wil
coxon–Mann–Whitney test. Analysis of four groups (e.g. roles of JNK
signaling in the proinflammatory effect of EKODE) was performed using
two-way ANOVA. The statistical analyses were performed using
GraphPad Prism 6 software, and P values less than 0.05 were considered
statistically significant. Gene expression data of ROS markers in CRC and
nontumor were derived from The Cancer Genome Atlas (TCGA) data
base through the UCSC Xena dataset (https://xena.ucsc.edu/).

2.9. qRT-PCR analysis of 16S rRNA in blood and spleen tissues
Blood (~100 μL) and spleen tissues (~30 mg) were collected for
analyzing the bacterial load. The total DNA was extracted using QIAamp
DNAeasy Blood & Tissue Kit (Qiagen) following the manufacturer’s in
struction with the addition of a bead-beating step. The quality of the
extracted DNA was measured using a NanoDrop Spectrophotometer
(Thermo Scientific) and qRT-PCR was performed using the same amount
of DNA (5 ng/mL) with the Maxima SYBR green Master Mix (Thermo
Fisher Scientific). The sequences of mouse-specific primer are listed in
Supplementary Table S2.

3. Results
3.1. EKODE is increased in the colon tissue of CRC mice

2.10. Measurement of cytokines and lipopolysaccharide (LPS) in plasma

In our previous study, we used an LC-MS/MS-based lipidomics to
systematically analyze how lipid metabolites are deregulated in an
AOM/DSS-induced CRC model in mice [7]. We re-analyzed the lip
idomics data (see heat-map analysis in Supplementary Fig. S1). Among
the lipid molecules detected in the colon (56 compounds in total), the
most dramatically increased compounds include three classes of lipids:
(i) 15-lipoxygegnase (LOX)-derived 13-hydroxyoctadecatrienoic acid
(13-HoTrE), (ii) CYP-derived epoxygenated fatty acids including 9
(10)-epoxyoctadecenoic acid (EpOME), 9(10)-, 12(13)-epoxyoctadeca
dienoic acid (EpODE), and 14 (15)- epoxyeicosatrienoic acid (EET),
and (iii) oxidative stress-derived EKODE (Fig. 1A). Previous research by
us and others have shown that the 15-LOX- and CYP-derived lipid me
tabolites are important mediators of CRC [7,9], while the roles of
EKODE in CRC are unknown. Therefore, here we focused on EKODE.
EKODE is produced when reactive oxygen species attack membrane
phospholipids [10] (Fig. 1B). We hypothesize that the colon tissues of
CRC mice have more severe oxidative stress, leading to higher concen
trations of EKODE. To test this hypothesis, we analyzed expression of

The concentration of MCP-1 in plasma was determined using a CBA
Mouse Inflammation Kit (BD Biosciences). The concentration of LPS in
plasma was quantified using an ELISA kit (MBS261904, MyBioSource)
following the manufacturer’s instructions.
2.11. Protein extraction and immunoblotting
For total protein extraction, RAW 264.7 or HCT -116 cells were
treated with 300 nM EKODE or DMSO vehicle in complete medium for
5–60min, then the cells were washed with cold PBS and lysed by RIPA
lysis buffer with a protease inhibitor cocktail (Boston BioProducts). For
nuclear protein extraction, nuclear and cytoplasmic extraction reagents
(#78833, Thermo Scientific) were used following the manufacturer’s
instructions. Protein concentrations were determined using BCA protein
assay kit (Thermo Scientific). The samples with equal amount of protein
(20 μg) were resolved using SDS/PAGE and transferred onto a nitro
cellulose membrane (LI-COR). The membrane was blocked in 5% bovine
3
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oxidative markers in the colon of control healthy mice vs.
AOM/DSS-induced CRC mice (see scheme of experiment in Fig. 2A).
First, we analyzed colon tumorigenesis in the mice. The control healthy
mice (not treated with AOM/DSS) had no tumors in the colon, while the
AOM/DSS-treated mice had an average of ~5 tumors per mouse
(Fig. 2B), with high expression of PCNA and active β-catenin in the colon
(Fig. 2C). In agreement with our results above (Fig. 1A), the
AOM/DSS-induced CRC mice had higher concentration of EKODE in the
colon (Fig. 2D), further supporting that EKODE is increased in CRC.
Next, we analyzed expression of oxidative markers in the colon of the
mice. Compared with control mice, the CRC mice had lower expression
of anti-oxidative genes, including Sod1 (encoding superoxide dismutase
1), Cat (encoding catalase), Gsr (encoding glutathione-disulfide reduc
tase), Gsta1 (encoding glutathione S-transferase A1), Gstm1 (encoding
glutathione S-transferase M1), and Hmox1 (encoding heme
oxygenase-1) in the colon. In addition, the CRC mice had higher
expression of a pro-oxidative gene Mpo (encoding myeloperoxidase) in
the colon (Fig. 2E). Overall, these results suggest that the CRC mice have
more severe oxidative stress in the colon.
After demonstrating that oxidative markers are altered in the mouse
model of CRC, we analyzed their expressions in human CRC patients
using the TCGA database. Compared with normal controls, the expres
sion of anti-oxidative genes (CAT, GSR, GSTA1, GSTM1, and HMOX1)
were significantly decreased, while the expression of the pro-oxidative
gene MPO was increased, in tumor samples of human CRC patients
(Fig. 3). Sod1 was reduced in mouse colon tumors (Fig. 2E), but it was
not changed in human CRC patients (Fig. 3). We also analyzed other
oxidative markers in the TCGA database. Glutathione peroxidase (GPX)
is an important redox protein [3]. We found that compared with normal
controls, the expressions of GPX1, GPX2, GPX4, GPX7, and GPX8 were

increased, while the expression of GPX3 was decreased, GPX5 and GPX6
were not changed, in CRC patients (Fig. S2). Since many of these
oxidative markers are regulated by the Nrf2 pathway [3], we also
analyzed the expressions of KEAP1 (a negative regulator of Nrf2
pathway) and NRF2. The expression of KEAP1 is increased, while the
expression of NRF2 is decreased, in CRC patients compared with controls
(Fig. 3). Overall, these results are largely consistent with our mouse data
(Fig. 2E), supporting that there is a more severe oxidative microenvi
ronment in colon tumors compared with normal colon tissues.
3.2. EKODE exacerbates colonic inflammation in mice
To understand the effects of EKODE on colonic inflammation, we
determined the effect of EKODE on development of DSS-induced colitis
in C57BL/6 mice. We treated mice with DSS, as well as EKODE (dose = 1
mg/kg/day, via intraperitoneal injection) or vehicle (see scheme of
animal experiment in Fig. 4A, and validating experiment of the DSS
model in Supplementary Fig. S3). We used the dose of 1 mg/kg/day,
since a previous study showed that intraperitoneal injection of a similar
lipid oxidation compound 4-hydroxynonenal (4-HNE), at a higher dose
(5 mg/kg/day), caused no toxic effect in mice [11]. Therefore, this
experimental design allows us to study the impact of low-dose EKODE
on colitis.
We found that EKODE treatment exaggerated DSS-induced colitis in
mice. Compared with vehicle-treated DSS mice, the EKODE-treated DSS
mice had more severe crypt damage in the colon (Fig. 4B), enhanced
colonic expression of genes that are associated with inflammation and
cell proliferation (Tnf-α, Jun, Myc, and Mki67) (Fig. 4C), higher protein
expression levels of phosphorylated JNK in the colon (Fig. S4A), and
higher infiltration of immune cells (CD45+ leukocytes, CD45+ F4/80+

Fig. 2. Oxidative stress and EKODE are increased in the colon of AOM/DSS-induced CRC mice. A, Scheme of animal experiment. B, Quantification of colon tumor in
mice (n = 7–8 mice per group). C, H&E histology and IHC staining of PCNA and β-catenin in colon (n = 7 mice per group, scale bars: 50 μm). D, Concentration of
EKODE in colon (n = 6–7 mice per group). E, Gene expression of Sod1, Cat, Gsr, Gsta1, Gstm1, Hmox1 and Mpo in colon (n = 6–7 mice per group). The results are
mean ± SEM. The statistical significance of two groups was determined using Student’s t-test or Wilcoxon-Mann-Whitney test.
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Fig. 3. TCGA databased showed that the expressions of antioxidant genes (CAT, GSR, GSTA1, GSTM1, HMOX1, and NRF2) were reduced, while the expressions of
pro-oxidant genes (MPO and KEAP1) were increased in CRC patients. The results are mean ± SEM. The statistical significance of two groups was determined using
Student’s t-test or Wilcoxon-Mann-Whitney test.

macrophages, and CD45+ Gr1+ neutrophils) in the colon (Fig. 4D).
Overall, these results demonstrate that treatment with low-dose EKODE
increases the severity of DSS-induced colitis in mice, demonstrating its
potent colitis-enhancing effect. We also analyzed the effect of EKODE on
expression of Hmox1, which is a down-stream target of the Nrf2 pathway
[3], and found that EKODE treatment did not change colonic expression
of Hmox1 in mice (Fig. S4B).
Colitis is associated with intestinal barrier dysfunction, leading to
translocation of LPS and bacteria from the gut into bloodstream and
other organs [12]. We analyzed whether EKODE treatment exaggerated
bacteria/LPS translocation in the DSS-induced colitis model. Compared
with vehicle-treated DSS mice, the EKODE-treated DSS mice had a
higher concentration of LPS in the plasma (Fig. 5A), and higher levels of
bacteria (as assessed by gene expression of 16S rRNA) in the blood and
spleen (Fig. 5B), demonstrating that EKODE treatment exaggerated
bacteria/LPS translocation. Bacterial invasion into tissues could lead to
tissue inflammation [12]. We analyzed whether EKODE treatment
exaggerated spleen inflammation. Compared with vehicle-treated DSS
mice, the spleen tissues of EKODE-treated DSS mice had increased
expression of pro-inflammatory cytokines Tnf-α and Il-1β and reduced
expression of an anti-inflammatory cytokine Il-10, demonstrating that
EKODE treatment exaggerated spleen inflammation (Fig. 5C). Overall,
these results demonstrate that EKODE treatment disrupted intestinal
barrier function, leading to enhanced LPS/bacterial translocation and
resulting in bacteria invasion-induced tissue inflammation.
To understand the mechanisms by which EKODE induced intestinal
barrier dysfunction, we analyzed colonic expression of Occludin, which
is a tight-junction protein involved in regulation of intestinal barrier
function [13]. We found that EKODE treatment reduced gene expression
of Occludin in the colon (Fig. 5D). This finding is further validated by
immunohistochemical staining, which showed that EKODE reduced
protein expression of Occludin in the colon (Fig. 5E). Overall, these
results suggest that EKODE treatment disrupted intestinal barrier

function, at least in part, through reducing colonic expression of
Occludin.
3.3. EKODE exacerbates colon tumorigenesis in mice
We determined the effect of EKODE on development of AOM/DSSinduced colon tumorigenesis in C57BL/6 mice. To do so, we stimu
lated the mice with AOM and DSS to initiate colon tumorigenesis, then
treated the mice with EKODE (dose = 1 mg/kg/day, via intraperitoneal
injection, the dose is the same as our colitis experiment as above in
Fig. 4) or vehicle during week 3 to week 4.5 post the AOM injection (see
scheme of animal experiment in Fig. 6A). This experimental design al
lows us to determine the extent to which systemic, short-time, treatment
with low-dose EKODE modulates the development of CRC.
We found that treatment with EKODE exaggerated AOM/DSSinduced colon tumorigenesis in mice. EKODE increased the number of
large-size (diameter > 2 mm) tumors, though it did not significantly
increase the number of small-size (diameter < 2 mm) tumors or the
number of total tumors (Fig. 6B). Furthermore, EKODE treatment
significantly increased average tumor size in mice (Fig. 6B). Immuno
histochemical staining showed that EKODE treatment increased
expression of CRC markers, such as PCNA and active β-catenin, in the
colon (Fig. 6C). In addition, we found that EKODE treatment increased
expression of pro-inflammatory genes (Mcp-1, Il-6, and Ifn-γ) and protumorigenic genes (Pcna, Myc, Jun, Ccnd-1, and Vegf) in the colon
(Fig. 6D), enhanced protein expression levels of IL-6 and phosphorylated
JNK in the colon (Figs. S5A–B), and higher concentration of MCP-1 in
plasma (Fig. S5C), demonstrating that EKODE exacerbated tumor
inflammation and colon tumorigenesis. Consistent with our result in
Fig. S4C, EKODE treatment did not change colonic expression of Hmox1
(Fig. S5D). Overall, these results demonstrate that EKODE has potent
CRC-enhancing effects.
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Fig. 4. EKODE increases DSS-induced colitis in mice. A, Scheme of animal experiment. The dose of EKODE is 1 mg/kg/day, administered via intraperitoneal in
jection. B, H&E staining of colon (n = 6 mice per group, scale bars: 50 μm). C, Gene expression of Tnf-α, Jun, Myc and Mki67 in colon (n = 4–7 mice per group). D,
FACS quantification of immune cells in colon (n = 5–7 mice per group). The results are mean ± SEM. The statistical significance of two groups was determined using
Student’s t-test or Wilcoxon-Mann-Whitney test.

3.4. EKODE induces inflammatory responses and activates NF-κB
signaling in both colon cancer cells and macrophage cells

inflammatory responses. We have determined the concentration of 300
nM, since this is similar to the concentrations of endogenous EKODE in
the colon of AOM/DSS-induced CRC mice (Fig. 2D).
In HCT-116 cells, treatment with EKODE induced gene expression of
pro-inflammatory cytokines (IL-6, IFN-γ, TNF-α) after 24-h treatment,
demonstrating its potent pro-inflammatory effect (Fig. 7A). Next, we
tested the effect of EKODE on NF-κB, which is an important signaling
pathway involved in inflammation [14]. After 30–60 min treatment,

After demonstrating that systemic treatment with EKODE increased
colitis and tumor inflammation in vivo, we tested whether EKODE
directly acted on colon cancer cells or immune cells to induce inflam
mation. To do so, we treated colon cancer (HCT-116) cells or macro
phage (RAW 264.7) cells with 300 nM EKODE, then examined
6

L. Lei et al.

Redox Biology 42 (2021) 101880

Fig. 5. EKODE induces intestinal barrier dysfunction and increases LPS/bacterial translocation. A, LPS concentration in plasma (n = 6–8 mice per group). B, Gene
expression of 16S rRNA gene in blood and spleen (n = 4–6 mice per group). C, Gene expression of Il-1β, Tnf-α and Il-10 in spleen (n = 4–7 mice per group). D, Gene
expression of Occludin in colon (n = 5–7 mice per group). E, IHC staining of Occludin in colon (n = 6–7 mice per group, scale bars: 50 μm). The results are mean ±
SEM. The statistical significance of two groups was determined using Student’s t-test or Wilcoxon-Mann-Whitney test.

Fig. 6. Treatment with EKODE exaggerates AOM/DSS-induced colon tumorigenesis in mice. A, Scheme of animal experiment (dose of EKODE = 1 mg/kg/day). B,
Quantification of colon tumor in mice (n = 8–9 mice per group). C, H&E histology and IHC staining of PCNA and β-catenin in colon (n = 8–9 mice per group, scale
bars: 50 μm). D, Gene expression of Mcp-1, Il-6, Ifn-γ, Pcna, Myc, Jun, Ccnd-1 and Vegf in colon (n = 8–9 mice per group). The results are expressed as means ± SEM.
The statistical significance of two groups was determined using Student’s t-test or Wilcoxon-Mann-Whitney test.
7
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Fig. 7. EKODE induces inflammation in human colon cancer HCT-116 cells and mouse macrophage RAW 264.7 cells. The cells were treated with 300 nM EKODE or
vehicle (DMSO). A, EKODE increased gene expression of pro-inflammatory cytokines in HCT-116 cells after 24-h treatment (n = 5 per group). B, EKODE enhanced
IκBα degradation in HCT-116 cells (n = 3 per group). C, EKODE increased nuclear translocation of p65 in HCT-116 cells (n = 3 per group). D, EKODE increased gene
expression of pro-inflammatory cytokines in RAW 264.7 cells after 24-h treatment (n = 5 per group). B, EKODE enhanced IκBα degradation in RAW 264.7 cells (n = 3
per group). C, EKODE increased nuclear translocation of p65 in RAW 264.7 cells (n = 3 per group). The results are mean ± SEM. The statistical significance of two
groups was determined using Student’s t-test or Wilcoxon-Mann-Whitney test. The cell culture experiments were performed with at least 3 independent repeats.

EKODE induced degradation of IκB-α and enhanced nuclear trans
location of p65, demonstrating that it activated the NF-κB signaling
pathway (Fig. 7B–C). A similar result was also observed in RAW 264.7
cells (Fig. 7D–F). Overall, these results demonstrate that treatment with
EKODE, at nM doses, induced inflammatory responses and activated
NF-kB pathway in both colon cancer cells and macrophage cells, illus
trating its potent pro-inflammatory effect in vitro. We also tested the
effects of EKODE on expression of Hmox1, which is a down-stream target
of the Nrf2 pathway [3], and found that 24-h treatment with 300 nM
EKODE had little effect on Hmox1 expression in vitro (Fig. S6).

3.5. EDKOE induces inflammation via JNK-dependent mechanisms in
vitro
To understand the mechanisms underlying the pro-inflammatory
effect of EKODE, we focused on JNK pathway, which plays critical
roles in regulating inflammation [15]. In both HCT-116 and RAW 264.7
cells, a 5–15 min treatment with 300 nM EKODE caused phosphoryla
tion of JNK (Fig. 8A–B), demonstrating that EKODE induced a rapid
activation of JNK signaling pathway. To determine the roles of JNK
signaling in the effect of EKODE in vitro, we tested the extent to which
co-administration of a JNK inhibitor, SP600125, attenuates the
pro-inflammatory effects of EKODE. We found that co-administration of
the JNK inhibitor abolished the pro-inflammatory effect of EKODE in
8
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Fig. 8. EKODE increases inflammation via JNK-dependent mechanisms in vitro. A-B, EKODE (concentration = 300 nM) increased JNK phosphorylation in HCT-116 and RAW 264.7 cells (n = 3 per group). C-D, Coadministration of a JNK inhibitor (SP600125, concentration = 100 nM) attenuated the pro-inflammatory effects of EKODE (300 nM) in HCT-116 and RAW 264.7 cells (n = 4–5 per group). The results are mean ± SEM.
The statistical significance of two groups was determined using Student’s t-test or Wilcoxon-Mann-Whitney test. Analysis of four groups was performed by two-way ANOVA. The cell culture experiments were performed
with at least 3 independent repeats.
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both HCT-116 and RAW 264.7 cells (Fig. 8C–D). Two-way ANOVA
analysis showed that there is a statistically significant interaction be
tween EKODE treatment (vehicle vs. EKODE) and JNK inhibitor treat
ment (with or without the JNK inhibitor) on inflammatory responses in
both HCT-116 and RAW 264.7 cells (Fig. 8C–D). Overall, these results
support a potential role of the JNK pathway in the pro-inflammatory
actions of EKODE in vitro.

agreement with previous studies which showed that oxidative stress and
associated lipid peroxidation compounds are increased in CRC [19].
Here, we showed that systemic, short-time, treatment with low-dose
EDKODE exaggerated DSS-induced colitis and AOM/DSS-induced CRC
in mice, supporting that EKODE is an important mediator of colonic
inflammation and CRC. In our animal experiments, we treated mice with
EKODE via intraperitoneal injection not oral administration, since
EKODE is chemically reactive and could be degraded in the upper
gastrointestinal tract and fail to reach the colon after oral administra
tion. We found that EKODE has potent and direct pro-inflammatory ef
fects, since treatment with nM EKODE induced expression of proinflammatory cytokines and activated NF-κB signaling in cultured
colon cancer cells and macrophage cells. Overall, these results support a
model that during development of CRC, the oxidative stress in colon
tumors leads to increased colonic concentration of EKODE, which can
target intestinal epithelial cells and immune cells to cause exaggerated
colonic inflammation, resulting in exacerbated development of CRC.
Thus, EKODE is an important endogenous mediator of colonic inflam
mation and CRC and could contribute to the mechanisms by which
oxidative stress regulates CRC development. Besides intestinal epithelial
cells and immune cells, the CRC-generated EKODE, as well as other lipid
oxidation-derived compounds, could directly interact with bacterial
cells that reside in the colon, leading to alteration of gut microbiota and
contributing to the development of CRC [20]. Further studies are needed
to better understand how CRC-associated redox environment interacts
with gut microbiota to affect the development of CRC.
Previous studies showed that EKODE can stimulate production of
dehydroepiandrosterone and corticosterone and activate Nrf2 signaling
in cultured cells [21–26]. The concentrations required by EKODE to
induce these effects are in high-μM range. For example, Wang et al.
showed that EDKOE at 10 μM activated Nrf2 signaling, while it did not
have such effects at lower concentrations [24]. This is higher than the
concentration of EKODE observed in our studies: for example, the con
centration of EKODE in the colon of AOM/DSS-induced CRC mice is
~150 pmol/g tissue (~0.15 μM). Therefore, the Nrf2-inducing activity
of EKODE may have a limited contribution to its impacts on develop
ment of inflammation and CRC as observed in this study. In support of
this notion, we found that treatment with 300 nM EKODE induced gene
expression of pro-inflammatory cytokines and activated NF-κB signaling
in vitro, while it had little effect on expression of Hmox1 (encoding heme
oxygenase-1), which is a down-stream target of the Nrf2 pathway [3]. In
addition, we found that in both DSS-induced colitis model and
AOM/DSS-induced CRC model, EKODE treatment did not alter colonic
expression of Hmox1 in mice. This could be, at least in part, due to the
low dose of EKODE (1 mg/kg/day) used in our animal experiments. Our
results are largely consistent with previous studies, which showed that
EKODE did not activate Nrf2 pathway at low doses [24].
Our results support that EKODE induces inflammation through JNKdependent mechanisms in vitro. We found that EDKOE induces a rapid
activation of JNK in both colon cancer (HCT-116) and macrophage
(RAW 264.7) cells; and co-administration of 100 nM of SP600125, a JNK
inhibitor, abolishes the pro-inflammatory effects of EKODE in these two
cell lines. Previous study has shown that SP600125 is a selective JNK
inhibitor: it inhibits JNK1, JNK2, and JNK3 with IC50 = 40–90 nM, and
inhibits other proteins at much higher concentrations [27]. Overall,
these results support a potential role of JNK signaling in the
pro-inflammatory effect of EKODE in vitro. We showed that EKODE
increased DSS-induced colitis and AOM/DSS-induced CRC in mouse
models, and further studies are needed to characterize the roles of JNK
signaling in the effects of EKODE in vivo. Previous studies showed that
treatment with JNK inhibitors (e.g. SP600125) attenuated DSS-induced
colitis in rodent models [28–30] and play critical roles in regulating
colon homeostasis [31], however, genetic ablation of JNK1 or JNK2
increased DSS-induced colitis in mice [32–34]. Regarding its roles in
CRC, JNK overexpression exacerbated AOM/DSS-induced CRC, but had
little impact on tumorigenesis triggered by Apc mutation [35].

4. Discussion
Previous studies showed that many oxidative markers, such as nitric
oxide, 8-Oxo-2′ -deoxyguanosine (8-oxodG), lipid oxidation compounds
(e.g. 4-hydroxynonenal and malondialdehyde), and antioxidant or prooxidative proteins (e.g. catalase and myeloperoxidase), are altered in
CRC, demonstrating that a more severe oxidative stress in CRC [2,3].
Oxidative stress has been suggested to contribute to the pathogenesis of
CRC, however, the molecular mechanisms by which the disturbed redox
homeostasis regulates the development of CRC are undefined [2]. Here
our central finding is that compared with control healthy mice, EKODE,
which is a redox stress-derived lipid signaling molecule [10], was
significantly increased in the colon of AOM/DSS-induced CRC mice.
Systemic, short-time treatment with low-dose EKODE increased the
severity of DSS-induced colitis and exaggerated the development of
AOM/DSS-induced CRC in mice, supporting that EKODE contributes to
the pathogenesis of colonic inflammation and colon tumorigenesis.
Regarding the mechanisms for the actions of EKODE, we found that
EKODE can directly target colon cancer cells and macrophage cells to
induce inflammation via JNK-dependent mechanisms. Overall, these
results support that EKODE is an important endogenous mediator of
colonic inflammation and colon tumorigenesis, and could contribute to
the mechanisms by which oxidative stress promotes CRC development.
The disturbed redox homeostasis in CRC could contribute to the high
concentrations of EKODE in colon tumors. We found that, in both mice
and humans, the expression of anti-oxidative markers, including cata
lase (encoding by Cat), glutathione-disulfide reductase (encoding by
Gsr), glutathione S-transferase A1 (encoding by Gsta1), glutathione Stransferase M1 (encoding by Gstm1), and heme oxygenase-1 (encoding
by Hmox1), are decreased, while the expression of a pro-oxidative
marker, myeloperoxidase (encoding by Mpo), is increased, in colon tu
mors. These results demonstrate that compared with normal colon tis
sue, the colon tumors have more severe redox stress. The disturbed
redox homeostasis in the colon tumor could contribute to the high
colonic concentration of EKODE through several possible mechanisms.
First, the increased redox stress, notably the reduced expression of
catalase and increased expression of myeloperoxidase, is linked with
increased colonic production of reactive oxygen species [16,17], which
can attack membrane phospholipids and lead to increased production of
lipid peroxidation-derived compounds including EKODE [10]. Second,
the decreased expression of glutathione S-transferases in colon tumors
could also lead to decreased metabolism of EKODE and thus contribute
to its high abundance in colon tumors. Previous research showed that
glutathione S-transferases are major enzymes involved in metabolism of
lipid peroxidation-derived α,β-unsaturated carbonyl compounds, such as
4-hydroxynonenal (4-HNE) and acrolein, converting these compounds
to their glutathione conjugates that are thought to be rapidly secreted
[18]. It is feasible that EKODE, which shares a similar α,β-unsaturated
carbonyl moiety, could also be metabolized by glutathione S-trans
ferases, though biochemical studies are needed to validate this. Our
previous study showed that compared with control healthy mice, the
plasma concentration of EKODE was not significantly increased in
AOM/DSS-induced CRC mice [7]. This could be due to the low chemical
and metabolic stability of EKODE in the circulation. Overall, our results
demonstrate that there is a more severe oxidative microenvironment in
colon tumor compared with normal colon tissue, leading to increased
production and/or decreased metabolism of EKODE and resulting in
increased concentration of EKODE in colon tumors. Our finding is in
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Treatment with JNK inhibitors attenuated early stage of CRC under
high-fat dietary conditions [36], as well as Apc mutation-induced CRC
[37]. These results suggest a complicated mechanism of JNK in medi
ating the pathogenesis of colitis and CRC.
In this study, a major limitation is that due to the limited amount of
colon tissues from mice, we did not measure the protein expression
levels of some markers. For example, we showed that compared with
control mice, the expressions of anti-oxidant genes, such as Sod1, Cat,
and Gsr, were reduced in the colon of the AOM/DSS-induced CRC mice,
but we did not measure the protein expression levels of these markers in
the mouse colon tissues. Further studies are needed to further validate
the gene expression results.
In summary, here we showed that EKODE, which is an endogenous
lipid peroxidation-derived compound, is increased in a mouse model of
CRC and exaggerates the development of colitis and CRC in mice. These
results support that EKODE could be a novel mechanistic linkage be
tween oxidative stress and CRC development.
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